Julia Zimmermann, PD, PhD

home / authors / julia-zimmermann-pd-phd

Julia Zimmermann, PD, PhD, is the CEO of terraplasma and Managing Director of hyped about science, which developed PHLAS, the at-home, cold plasma skin care device.

Articles

Revolutionizing Acne Treatments and Skin Care with Cold Plasma Technology

Revolutionizing Acne Treatments and Skin Care with Cold Plasma Technology

Marie Bosslett, Assistant Editor;Julia Zimmermann, PD, PhD
May 20th 2025

Julia Zimmermann, PD, PHD's innovative cold plasma technology for acne treatment, developed through extensive research, promises effective results for clearer skin.

Julia Zimmermann PD, PhD, Demonstrates PHLAS, A New Cold Plasma Skin Care Device

Julia Zimmermann PD, PhD, Demonstrates PHLAS, A New Cold Plasma Skin Care Device

Marie Bosslett, Assistant Editor;Julia Zimmermann, PD, PhD
May 19th 2025

Discover how Julia Zimmermann, PD, PhD's PHLAS innovates cold plasma technology for skin care, enhancing treatments for acne and skin health.

Latest Updated Articles

2 KOLs are featured in this series.
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?
Published: November 17th 2023 | Updated: June 12th 2025
POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?
Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria
Published: June 9th 2025 | Updated: June 12th 2025
Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria
Late-Breaking Data: Lebrikizumab Demonstrates Efficacy in Patients With Skin of Color With AD
Published: June 7th 2025 | Updated: June 12th 2025
Late-Breaking Data: Lebrikizumab Demonstrates Efficacy in Patients With Skin of Color With AD
Evaluating Stress Levels in AD Treatment Plans
Published: November 9th 2023 | Updated: June 12th 2025
Evaluating Stress Levels in AD Treatment Plans
Dupilumab Significantly Enhances Quality of Life and Reduces Cumulative Impairment in Patients with Moderate to Severe Atopic Dermatitis
Published: June 7th 2025 | Updated: June 12th 2025
Dupilumab Significantly Enhances Quality of Life and Reduces Cumulative Impairment in Patients with Moderate to Severe Atopic Dermatitis
© 2025 MJH Life Sciences

All rights reserved.